A Phase 2 interventional study of Methamphetamine and Sterile Saline in Methamphetamine Intoxication, Methamphetamine Disorders and Methamphetamine Abuse, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Clear Scientific, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).
Clear Scientific, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).
Drug: Methamphetamine · Drug: Sterile Saline
Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103
Drug: Methamphetamine · Drug: CS-1103
Methamphetamine HCl for intravenous administration
Sterile Saline for intravenous administration
CS-1103 for intravenous administration
Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations
Physical examinations
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)
Digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted.
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by vital signs
Blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parameters
Clinical chemistry, hematology, coagulation, and urinalysis
Time frame: 3 days plus follow-up on Day 10
Time course and magnitude of urine excretion of methamphetamine
Measurement of concentration of methamphetamine in urine
Time frame: 48 hours
Time course of CS-1103 blood and urine concentrations
Measurement of plasma and urine concentrations of CS-1103
Time frame: 48 hours
Ran from Feb 2026 to primary completion in Oct 2026, 8 months.
Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CS-1103